PDA Asks for Input on CMC Post-Approval Changes
PDA is conducting a survey of industry members challenged by the complexity of making post-approval changes.
The Parenteral Drug Association (PDA) has established a taskforce to explore opportunities to reduce the complexity of chemistry, manufacturing, and controls (CMC) regulatory post-approval change (PAC) processes and is conducting a survey to collect data on current (CMC) PAC processes. With current divergent requirements, PDA wrote in the letter on Dec. 15, 2016, the path to global approval of a post-approval change may increase the risk of drug shortages and incentivizes companies to keep things the way they are rather than facilitating modernization, maintaining a state of control, and achieving product realization-the objectives of International Council for Harmonization (ICH) Q10.
PDA is inviting individuals challenged by the complexity of making PACs to complete the survey. The association says it will release preliminary results at the 2017 PDA Annual Meeting from April 3–5, 2017 in Anaheim, CA. The survey will be available for completion until February 15, 2017. Anyone with questions is encouraged to contact Morgan Holland, of the PDA Science and Regulatory Affairs Department.
Source: PDA
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
